What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

Original reporting
Published Nov 8, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 8, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$ZBHNeutralMed
01

Why it matters

Earnings release provides fresh guidance and financial metrics that can shift investor sentiment and short‑term price action.

02

Market read

The earnings beat on margin and buyback plan may support the stock, while the EPS miss could limit upside; overall impact is moderate.

03

What to watch

Potential upside from the new Monogram robotic system and the exclusive TMINI partnership with THINK Surgical.

Relevance 7/10Novelty 7/10Timing: after‑hours release

Background

Zimmer Biomet reported its Q3 results, highlighted a 13% rise in technology and data sales, a 2.6% decline in global knee sales, and outlined future product timelines.

Company-level read

Ticker impact

$ZBHNeutralHigh confidence
Context

Q3 earnings disclosed GAAP EPS of $1 (down from $1.16) and raised full-year sales growth outlook to 4.4‑4.9%, plus a $1 bn share‑repurchase plan for 2026.

Expected impact

likely modest pressure as investors price in lower GAAP EPS, offset by higher margin outlook and buyback commitment

Evidence & confidence

The earnings numbers are new and material; the mixed results create a balanced market reaction.

Market effects

Orthopedic device sector may see modest re‑rating as peers compare knee‑sales trends and robotic‑system rollouts.

U.S. healthcare investors may adjust exposure to surgical‑technology stocks.

Limited; primarily affects U.S. and European med‑tech investors.

Counterpoint

Buy on the raised margin outlook and upcoming Monogram launch, betting the EPS miss is temporary.

Key entities

  • Zimmer Biomet Holdings, Inc.

    Medical device manufacturer reporting Q3 earnings.

  • THINK Surgical

    Partner in exclusive TMINI robotic system distribution.

Related articles

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.

$ZBHMedAI 8/10

Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript

Zimmer Biomet (ZBH) reported Q3 2026 net sales of $2.63B, up 3.7% in constant currency. Growth was driven by hips, S.E.T., and technology, while knees declined 2.6%. The company raised its 2026 guidance, expecting 3% to 3.5% constant currency sales growth and $8.50 to $8.60 adjusted EPS. Strategic priorities include sales force transition, robotics expansion, and diversification.